Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Chief Business Officer | February 10, 2025 | February 27, 2025 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | COO & GC | April 15, 2026 | April 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyell Immunopharma, Inc.
Report date February 10, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,500 |
Reported balance
After 2025-02-10 transaction · row 1
1 source rowRow 1 · 2025-02-10 · Grant · Acquired 112,500 · Balance 162,500 F1: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2035-02-09 | Direct | 450,000 |
Reported balance
After 2025-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-10 · Grant · Acquired 450,000 · Balance 450,000 F2: 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.55 · Expires 2035-02-09 | Direct | 56,250 |
Reported balance
After 2025-02-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-10 · Grant · Acquired 56,250 · Balance 56,250 F3: The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria. |
Filing footnotes · ownership attribution and instrument terms
F1: 12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
F2: 12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
F3: The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.
Structure Therapeutics Inc.
Report date April 15, 2026 · Filed April 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 184,614 |
Reported balance
After 2026-04-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 184,614 · Balance 184,614 F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. F2: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of April 15, 2026, subject to Reporting Person's continued service on such dates. |
| Share option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.08 · Expires 2036-04-14 | Direct | 223,776 |
Reported balance
After 2026-04-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-15 · Grant · Acquired 223,776 · Balance 223,776 F3: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs. F4: One-fourth of the shares vest on the first anniversary of April 15, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date. F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
F2: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one Ordinary Share of the Issuer. The RSUs vest 1/4th annually on each anniversary of April 15, 2026, subject to Reporting Person's continued service on such dates.
F3: The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's ADSs.
F4: One-fourth of the shares vest on the first anniversary of April 15, 2026, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service through each such vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Metsera, Inc.
Report date November 13, 2025 · Filed November 13, 2025
Section 16 reporting ended · disclosed 2025-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 12,500 |
Reported balance
After 2025-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-13 · Grant · Acquired 12,500 · Balance 12,500 F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.25 · Expires 2035-05-19 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-13 · Disposition to issuer · Disposed 46,875 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F6: This option provided for vesting in 48 substantially equal monthly installments from May 20, 2025. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2035-04-14 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-13 · Disposition to issuer · Disposed 325,000 · Balance 0 F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options, F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger. F7: This option was granted on April 15, 2025. The option provided for vesting as to 25% of the shares initially subject to the option on the first anniversary of April 14, 2025, and as to 1/48th of the shares initially subject to the option on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), net of all applicable withholding taxes, plus
F2: (Continued from footnote 1) (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
F3: Pursuant to the Merger Agreement, each outstanding and unexercised option immediately prior to the Effective Time, whether vested or unvested, was cancelled in exchange for the right to receive (x) an amount in cash equal to the product of (i) the excess, if any, of the Closing Amount minus the exercise price of such option, multiplied by (ii) the number of shares of Common Stock subject to such option immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) one CVR for each share of the Common Stock subject to such stock option immediately prior to the Effective Time. In the case of any unvested stock options, the cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the stock options,
F4: (Continued from footnote 3) except that all such payments will become vested upon the first anniversary of the closing of the Merger, subject to the holder's continued service with the Parent or its subsidiaries through the first anniversary of the Merger.
F5: On November 12, 2025, the Reporting Person was granted restricted stock units ("RSUs") under the Company's 2025 Incentive Award Plan in a transaction exempt under Rule 16b-3. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in 36 substantially equal monthly installments from November 12, 2025. Pursuant to the Merger Agreement, all RSUs were cancelled and converted into the right to receive (x) an amount of cash equal to the Closing Amount multiplied by the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, net of all applicable withholding taxes, and (y) a number of CVRs equal to the under of the shares of Common Stock underlying the RSU. The cash payment and the CVRs are subject to the same vesting schedule terms as were applicable to the RSUs.
F6: This option provided for vesting in 48 substantially equal monthly installments from May 20, 2025.
F7: This option was granted on April 15, 2025. The option provided for vesting as to 25% of the shares initially subject to the option on the first anniversary of April 14, 2025, and as to 1/48th of the shares initially subject to the option on each monthly anniversary thereafter.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-10 · Disposition to issuer · Disposed 113,145 · Balance 241,158 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"). Row 2 · 2023-03-10 · Disposition to issuer · Disposed 241,158 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2027-07-16 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 220,000 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2028-04-15 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 87,050 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.78 · Expires 2029-04-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Disposition to issuer · Disposed 152,110 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2030-04-02 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Disposition to issuer · Disposed 170,396 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F6: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.88 · Expires 2031-04-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-10 · Disposition to issuer · Disposed 90,310 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F7: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-10 · Disposition to issuer · Disposed 111,111 · Balance 0 F8: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration").
F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and the holder thereof was entitled to the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable-exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
F6: One-fourth of the options vested on April 3, 2021, and one-sixteenth of the options vest each quarter thereafter.
F7: One-fourth of the options vested on April 15, 2022, and one-sixteenth of the options vest each quarter thereafter.
F8: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2020 Filed Dec 11, 2020 16:22 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 600 | $7.78 | $4,668.00 |
DisclosureSEC source: 0001209191-20-062937 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:47 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,700 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-049166 · doc4.xml · derivative · entry 3 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 26,700 shares Expires 2027-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:47 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 26,700 | $20.05 | $535,281.60 |
DisclosureSEC source: 0001209191-20-049166 · doc4.xml · nonDerivative · entry 2 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,865 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $20.00 to $20.415. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:47 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 26,700 | $7.78 | $207,726.00 |
DisclosureSEC source: 0001209191-20-049166 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2020 Filed Aug 28, 2020 17:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,600 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-048673 · doc4.xml · derivative · entry 6 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,700 Underlying: Common Shares · 2,600 shares Expires 2027-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| August 28, 2020 Filed Aug 28, 2020 17:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 2,600 | $20.02 | $52,052.00 |
DisclosureSEC source: 0001209191-20-048673 · doc4.xml · nonDerivative · entry 4 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,865 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $20.00 to $20.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 28, 2020 Filed Aug 28, 2020 17:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 2,600 | $7.78 | $20,228.00 |
DisclosureSEC source: 0001209191-20-048673 · doc4.xml · nonDerivative · entry 3 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 17:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-048673 · doc4.xml · derivative · entry 5 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,300 Underlying: Common Shares · 100 shares Expires 2027-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 17:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 100 | $20.00 | $2,000.00 |
DisclosureSEC source: 0001209191-20-048673 · doc4.xml · nonDerivative · entry 2 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,865 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| August 26, 2020 Filed Aug 28, 2020 17:41 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 100 | $7.78 | $778.00 |
DisclosureSEC source: 0001209191-20-048673 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 17:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-20-047963 · doc4.xml · derivative · entry 3 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,400 Underlying: Common Shares · 600 shares Expires 2027-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: All of the shares under this option have vested. Of the vested portion of this option, 155,000 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 17:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 600 | $20.00 | $12,000.00 |
DisclosureSEC source: 0001209191-20-047963 · doc4.xml · nonDerivative · entry 2 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,865 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 17:04 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Exercise / conversionCommon Shares | 600 | $7.78 | $4,668.00 |
DisclosureSEC source: 0001209191-20-047963 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:12 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 170,396 | $0.00 Strike: $8.08 | $0.00 |
DisclosureSEC source: 0001209191-20-023795 · doc4.xml · derivative · entry 2 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,396 Underlying: Common Shares · 170,396 shares Expires 2030-04-02 F2 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 3, 2021, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 17:12 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 111,268 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-023795 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,865 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 3, 2021, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| December 30, 2019 Filed Dec 30, 2019 19:14 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Stock | 19,018 | $15.55 | $295,729.90 |
DisclosureSEC source: 0001209191-19-062189 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,597 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 152,110 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · derivative · entry 7 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,110 Underlying: Common Shares · 152,110 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 152,110 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · derivative · entry 6 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 152,110 shares Expires 2029-04-04 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F5 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 87,050 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · derivative · entry 5 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,050 Underlying: Common Shares · 87,050 shares Expires 2028-04-15 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 87,050 | $0.00 Strike: $21.87 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · derivative · entry 4 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 87,050 shares Expires 2028-04-15 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F4 · derivative.exercise_date: 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $7.78 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · derivative · entry 3 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Shares · 310,000 shares Expires 2027-07-16 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the shares underlying the option vested on July 17, 2018, and 1/16 of the common shares underlying the option vest each quarter thereafter, subject to the Reporting Person providing continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $11.30 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · derivative · entry 2 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 310,000 shares Expires 2027-07-16 F2 · shares: Each reported acquisition and disposition of an option for the like number of shares consisted of an amendment to an outstanding option, resulting in the deemed cancellation of the "old" option and grant of a replacement option. F3 · derivative.exercise_date: 1/4 of the shares underlying the option vested on July 17, 2018, and 1/16 of the common shares underlying the option vest each quarter thereafter, subject to the Reporting Person providing continuous service to the Issuer or its affiliates on each such date. The replacement option provides that the Reporting Person cannot exercise the currently vested portion of the replacement option for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 16:58 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 53,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-047546 · doc4.xml · nonDerivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,615 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. The RSUs shall vest as follows: (i) 1/3 of the total shares subject to the RSUs shall vest at the later occurrence of (a) the achievement of certain milestones and (b) the first anniversary of the grant date; and (ii) 2/3 of the total shares subject to the RSUs shall vest as follows: 1/8 vesting on the first anniversary of the grant date and 7/8 vesting in seven even installments each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 05, 2019 Filed Apr 9, 2019 18:19 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 152,110 | $0.00 Strike: $24.44 | $0.00 |
DisclosureSEC source: 0001209191-19-024142 · doc4.xml · derivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,110 Underlying: Common Stock · 152,110 shares Expires 2029-05-04 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 5, 2020, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 18:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 87,050 | $0.00 Strike: $21.87 | $0.00 |
DisclosureSEC source: 0001209191-18-025455 · doc4.xml · derivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,050 Underlying: Common Stock · 87,050 shares Expires 2028-04-15 F1 · derivative.exercise_date: 1/4 of the common shares underlying this option vest on April 16, 2019, and 1/16 of the common shares underlying this option vest at the end of each quarter thereafter measured from April 16, 2019, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| July 17, 2017 Filed Jul 18, 2017 06:33 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantEmployee Stock Option (Right to Buy) · Derivative | 310,000 | $0.00 Strike: $11.30 | $0.00 |
DisclosureSEC source: 0001209191-17-045396 · doc4.xml · derivative · entry 1 Lang Matthew · CIK 0001712069 · General Counsel & Corp. Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,000 Underlying: Common Stock · 310,000 shares Expires 2027-07-16 F1 · derivative.exercise_date: 1/4 of the shares underlying the option vest and become exercisable on July 17, 2018; and 1/16 of the shares underlying the option vest at the end of each quarter thereafter, measured from July 17, 2018, subject to the Reporting Person providing continuous service to the Issuer or its affiliates on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.